Comparison of Two Different Antibody Clones of Programmed Cell Death Ligand 1 (PD-L1) with Immunohistochemical Method on Various Tumors


TOKAT F.

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, vol.4, no.4, pp.299-303, 2020 (Journal Indexed in ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 4 Issue: 4
  • Publication Date: 2020
  • Doi Number: 10.14744/ejmo.2020.44540
  • Title of Journal : EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
  • Page Numbers: pp.299-303

Abstract

Objectives: Programmed cell death ligand 1 (PD-L1) is the most important immune checkpoint protein in immune defense against tumors. PD-1/PD-L1 inhibitors are considered an option in cancer treatments. The evaluation of PD-L1 immunohistochemical staining is used as a biomarker to determine the decision and response of the use ofthese inhibitory drugs. There is a wide variety of clones and platforms for the PD-L1 antibody, and each pathology department uses different clones and platforms which causes confusion. Therefore, in this study, we evaluated the immunohistochemical staining of different clones in the same tumor.